Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101053-101053
Closed Access | Times Cited: 18

Showing 18 citing articles:

Novel Nano-sized N-Thiazolylpyridylamines Targeting CDK2: Design, Divergent Synthesis, Conformational Studies, and Multifaceted In Silico Analysis
Samir Bondock, Nada Alabbad, Aisha Hossan, et al.
Chemico-Biological Interactions (2025), pp. 111366-111366
Closed Access | Times Cited: 2
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Hossam Nada, Yongseok Choi, Sung-Do Kim, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 8
Rho-GTPases subfamily: cellular defectors orchestrating viral infection
Beibei Zhang, Shuli Li, Juntao Ding, et al.
Cellular & Molecular Biology Letters (2025) Vol. 30, Iss. 1
Open Access
Miniaturized Modular Click Chemistry‐enabled Rapid Discovery of Unique SARS‐CoV‐2 Mpro Inhibitors With Robust Potency and Drug‐like Profile
Mianling Yang, Myoung Kyu Lee, Shenghua Gao, et al.
Advanced Science (2024)
Open Access | Times Cited: 3
Undeveloped Region in Target-Strategies and Potential in Antiviral Drug Discovery
Shaoqing Du, Xinyong Liu, Xueping Hu, et al.
Pharmaceutical Fronts (2025)
Open Access
Fabrication of novel purine nucleoside derivatives bearing a cinnamic acid moiety for controlling plant viral diseases: synthesis, anti‐tobacco mosaic virus activity, and mechanistic study
Long Cheng, Xiang Zhou, Yong Huang, et al.
Pest Management Science (2025)
Closed Access
Fabrication of novel activated carbon/carbonized cuttlefish bone bio-based adsorbent for Carbamazepine drug adsorption: high efficiency, biocompatibility, and environmental safety
Samar M. Mahgoub, Rania Abdelazeem, S. A. Abdel Moaty, et al.
International Journal of Environmental & Analytical Chemistry (2025), pp. 1-25
Closed Access
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Huijie Bian, Chen Liang, Zheng Zhang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Discovery of Novel Fused-heterocycle-bearing Diarypyrimidine Derivatives as HIV-1 Potent NNRTIs Targeting Tolerant Region I for Enhanced Antiviral Activity and Resistance Profile
Jiaojiao Dai, Xiangyi Jiang, Heng Gao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117033-117033
Closed Access | Times Cited: 3
Design and optimization of piperidine-substituted thiophene[3,2-d]pyrimidine-based HIV-1 NNRTIs with improved drug resistance and pharmacokinetic profiles
Yanying Sun, Zhenzhen Zhou, Zhongling Shi, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 7, pp. 3110-3124
Open Access | Times Cited: 2
Design of mucoadhesive thiomer/organically modified montmorillonite nanocomposites: Evaluation of controlled drug release
Alexander Sepúlveda-Córdova, Tomás Fernández-Martínez, Víctor H. Campos-Requena
Journal of Drug Delivery Science and Technology (2024) Vol. 98, pp. 105865-105865
Closed Access | Times Cited: 2
The latest developments in the design and discovery of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV
Junyi Li, Bing Ye, Shenghua Gao, et al.
Expert Opinion on Drug Discovery (2024), pp. 1-18
Closed Access | Times Cited: 1
Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral Proteins
Hangyu Wang, Panpan Li, Jie Shen, et al.
Journal of Microbiology and Biotechnology (2024) Vol. 34, Iss. 7, pp. 1376-1384
Open Access | Times Cited: 1
Post-translational modifications in drug resistance
Chenggui Miao, Yu Huang, Cheng Zhang, et al.
Drug Resistance Updates (2024) Vol. 78, pp. 101173-101173
Closed Access
Viral Protein Dimerization Quality Control: A Design Strategy for a Potential Viral Inhibitor
Shaoqing Du, Xinyong Liu, Xueping Hu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Meeting Report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20–24, 2024, organized by the International Society for Antiviral Research
Stephen R. Welch, John P. Bilello, Kara Carter, et al.
Antiviral Research (2024) Vol. 232, pp. 106037-106037
Closed Access
Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies
Nida Kalam, Vinod Balasubramaniam
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 12
Open Access
Page 1

Scroll to top